-
NextCure Inc NasdaqGS:NXTC NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Location: 9000 Virginia Manor Road, Beltsville, MD, 20705, United States | Website: https://www.nextcure.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-36.09M
Cash
55.86M
Avg Qtr Burn
-10.3M
Short % of Float
1.54%
Insider Ownership
8.91%
Institutional Own.
48.29%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NC410 (LAIR-2 fusion)+ pembrolizumab Details Cancer, Ovarian cancer, Colorectal cancer | Phase 1b Update | |
LNCB74 (B7-H4 ADC) Details Solid tumor/s, Cancer, Ovarian cancer, Breast cancer, Endometrial cancer | Phase 1 Data readout | |
NC525 (LAIR-1 mAb) Details Solid tumor/s, Cancer, Acute myeloid leukemia | Phase 1a Update | |
NC318 (S15) Details Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma | Failed Discontinued | |
NC318 (S15) + pembrolizumab Details Solid tumor/s, Cancer | Failed Discontinued | |
NC762 (B7-H4 mAb) Details Cancer, Solid tumor/s, Lung cancer, Ovarian cancer, Breast cancer | Failed Discontinued |